Abstract Number: 1235 • 2019 ACR/ARP Annual Meeting
Monthly Dosing of ImmTOR Tolerogenic Nanoparticles Combined with Pegylated Uricase (Pegadricase) Mitigates Formation of Anti-Drug Antibodies Resulting in Sustained Uricase Activity in Symptomatic Gout Patients
Background/Purpose: Gout is caused by the deposition of monosodium urate (MSU) crystals in joints due to chronic hyperuricemia. Long term treatment focuses on reducing sUA…Abstract Number: 1236 • 2019 ACR/ARP Annual Meeting
Subcutaneous or Oral Methotrexate Exposure and Response to Pegloticase in Uncontrolled Gout Patients in a Community Rheumatology Practice
Background/Purpose: Pegloticase is an infused biologic for uncontrolled gout patients that is highly effective but can cause anti-drug antibodies that lead to a lack of…Abstract Number: 1237 • 2019 ACR/ARP Annual Meeting
Treatment with OLT1177™, an Oral NLRP3 Inflammasome Inhibitor, Reduces Systemic Inflammation During Gout Flares in Humans
Background/Purpose: Gout flares are characteristically mediated by the pro-inflammatory cytokine interleukin (IL)-1β. Uptake of monosodium urate (MSU) crystals by macrophages activates the nucleotide-binding domain and…Abstract Number: 1240 • 2019 ACR/ARP Annual Meeting
A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study
Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the…Abstract Number: 1855 • 2019 ACR/ARP Annual Meeting
Evaluating the OMERACT Definitions of Ultrasound Gout Structural Lesions in the Diagnosis of Gout
Background/Purpose: To evaluate ultrasound (US) as a diagnostic tool for gout with positive urate crystal microscopy as the gold standard, using the OMERACT US working…Abstract Number: 1860 • 2019 ACR/ARP Annual Meeting
Using Electronic Visits (E-Visits) to Achieve Goal Serum Urate Levels in Patients with Gout in a Rheumatology Practice: A Pilot Study
Background/Purpose: Gout is a highly prevalent form of inflammatory arthritis associated with increased morbidity and mortality, and the burden of gout on the healthcare system…Abstract Number: 1937 • 2019 ACR/ARP Annual Meeting
Mononuclear Leukocyte DNA Methylome Imprinting of Networked Signaling and Immunity Regulatory Pathways in Gout
Background/Purpose: Gout encompasses acute arthritis flares mediated by innate autoinflammatory responses to urate crystals, chronic granulomatous tophi, and synovitis promoting bone erosion and soft tissue…Abstract Number: 2047 • 2019 ACR/ARP Annual Meeting
Time-trends in Opioid Use Hospitalizations in Common Musculoskeletal Conditions: Gout, Osteoarthritis, Rheumatoid Arthritis, Fibromyalgia, and Low Back Pain
Background/Purpose: Rates of opioid abuse and associated mortality is a problem of epidemic proportion in the U.S. To our knowledge, limited data are available on…Abstract Number: 2050 • 2019 ACR/ARP Annual Meeting
Association of Gout with Vitamin D: A Population-Based Study
Background/Purpose: Prior research showed conflicting results about the association of vitamin D with gout. We aimed in this study to quantify vitamin D levels in…Abstract Number: 2051 • 2019 ACR/ARP Annual Meeting
Factors in Achieving Serum Uric Acid Target and the Occurrence of Gouty Arthritis: A Cross-sectional Study Based on Japanese Health Insurance Claim Data
Background/Purpose: The number of gout attacks can be reduced by achieving and maintaining serum uric acid (sUA) at or below 6.0 mg/dL, a level uniformly…Abstract Number: 2053 • 2019 ACR/ARP Annual Meeting
Risk of Non-vertebral Fracture in Gout Compared to Rheumatoid Arthritis
Background/Purpose: Gout is a common inflammatory arthritis, characterized by hyperuricemia leading to crystallization of uric acid in joints. Proinflammatory cytokines have been known as an…Abstract Number: 2054 • 2019 ACR/ARP Annual Meeting
Epidemiology of Gout in South Korea with the National Health Insurance Corporation Database
Background/Purpose: Gout is the most common inflammatory arthritis that results from chronic elevation of uric acid levels above the saturation point for monosodium urate crystal…Abstract Number: 2058 • 2019 ACR/ARP Annual Meeting
Pharmacoepidemiology of Gout Treatment in Office-based Outpatient Care from 2009- 2016
Background/Purpose: Studies show that gout treatment remains suboptimal in the United States (US). Despite clear benefits for urate-lowering therapy (ULT) for chronic gout, surveyed physicians…Abstract Number: 2133 • 2019 ACR/ARP Annual Meeting
Acute Myocardial Infarction in Rheumatoid Arthritis, Gout, and Osteoarthritis: A Retrospective Study Using the National Inpatient Sample from 2002-2016
Background/Purpose: Inflammation is a risk factor in the development of cardiovascular disease. The proposed etiology centers around accelerated atherosclerosis involving various cytokines in the TNF…Abstract Number: 2732 • 2019 ACR/ARP Annual Meeting
The Relationship Between Gout and Cardiovascular Disease Outcomes: A Health Data Linkage Study of 1 Million New Zealanders Using Population-level Cardiovascular Risk Prediction Equations
Background/Purpose: Some studies have reported that gout is an independent risk factor for cardiovascular events. Furthermore, urate-lowering therapy such as allopurinol may be associated with…
Simple Search Results
Didn't find what you were looking for? Try the Advanced Search »
Didn't find what you were looking for? Try the Advanced Search »